But much more basic research on disease pathways is needed to entice more pharmaceutical companies back to the field.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Dolgin, E. Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov 13, 641–642 (2014). https://doi.org/10.1038/nrd4411
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4411
This article is cited by
-
Meta-analysis of genomic variants and gene expression data in schizophrenia suggests the potential need for adjunctive therapeutic interventions for neuropsychiatric disorders
Journal of Genetics (2019)
-
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine
Nature Reviews Drug Discovery (2017)